ALX Oncology Holdings Inc. (ALXO) Stock Price

1.42 ▲ +0.05 (+3.65%)
Open: 1.37 Vol: 266.32K Day's range: 1.37 - 1.48 Dec 05, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ALXO Technical Analysis
5 mins 30 mins Hourly Daily Weekly
NEUTRAL BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 1.43▼ 1.42▲ 1.43▼ 1.33▲ 1.40▲
MA10 1.43▼ 1.43▼ 1.41▲ 1.38▲ 1.56▼
MA20 1.43▼ 1.40▲ 1.36▲ 1.38▲ 1.28▲
MA50 1.40▲ 1.33▲ 1.36▲ 1.57▼ 1.02▲
MA100 1.34▲ 1.38▲ 1.42▲ 1.23▲ 4.39▼
MA200 1.34▲ 1.40▲ 1.44▼ 0.92▲ 7.03▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.002▼ -0.002▼ 0.010▲ 0.002▲ 0.005▲
RSI 53.109▲ 59.558▲ 60.879▲ 50.167▲ 53.536▲
STOCH 70.556     45.555     64.295     28.820     31.691    
WILL %R -40.000     -40.909     -27.273     -52.174     -64.885    
CCI 8.046     24.301     64.294     2.770     -38.637    
Latest Filters Detected On ALXO
RSI $ALXO RSI(14) Crossed Above 50 Set Alert
▲ MACD $ALXO MACD(12,26,9) Crossed Above Signal Line Set Alert
MA $ALXO Price Crossed Above MA(26) Set Alert
MA $ALXO Price Crossed Above MA(13) Set Alert
ALX Oncology Holdings Inc. News
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025
Sunday, December 07, 2025 09:24 PM
ALX Oncology is a clinical-stage biotech company developing new cancer therapies aimed at improving patient outcomes. Its lead candidate, evorpacept, is being tested in multiple cancer types.
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with ...
Sunday, December 07, 2025 05:21 AM
Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an ...
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with ...
Sunday, December 07, 2025 05:07 AM
Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent ...
ALXO historical stock data
date open high low close volume
05/12/25 1.37 1.48 1.37 1.42 266,319
04/12/25 1.33 1.395 1.30 1.37 147,668
03/12/25 1.27 1.33 1.20 1.32 346,445
02/12/25 1.32 1.35 1.20 1.20 223,768
01/12/25 1.33 1.4056 1.30 1.32 193,523
28/11/25 1.38 1.425 1.35 1.37 42,778
26/11/25 1.45 1.47 1.35 1.38 143,660
25/11/25 1.52 1.54 1.445 1.45 85,989
24/11/25 1.43 1.555 1.43 1.51 166,923
21/11/25 1.35 1.45 1.29 1.43 178,057
Quote Details
52wk Low:0.404
52wk High:2.27
Vol:266.32K
Avg Vol(3m):6.3M
1Y Chng:-12.35%
1M Chng:-18.86%
Add to Watch List
More Information
Index US Composite
Market Cap. 74.28M